

The Journal of Rheumatology

VOLUME 39: SUPPLEMENT 89

JULY 2012

Proceedings of the Second Update on Psoriatic Disease University Federico II Congress Center Naples, Italy July 6–7, 2011

Foreword: Second Update on Psoriatic Disease <i>J.M.H. Moll</i>	1
New Insights into the Concept of Psoriatic Disease <i>R. Scarpa</i>	4
Pathogenetic Overview of Psoriatic Disease <i>M. Haroon, O. FitzGerald</i>	7
The Synovio-entheseal Complex and Its Role in Tendon and Capsular Associated Inflammation <i>D. McGonagle, S.Z. Aydin, A.L. Tan</i>	11
Th17 and IL-23 in the Pathogenesis of PsA and SpA <i>A. Cauli, A. Mathieu</i>	15
Remission in PsA <i>A. Caperon, P.S. Helliwell</i>	19
New Insights in Occult PsA <i>C. Palazzi, S. D'Angelo, E. Lubrano, I. Olivieri</i>	22
Metabolic Syndrome in Patients with Psoriatic Disease <i>J.M. Gelfand, H. Yeung</i>	24
Enteseal Power Doppler Ultrasonography: A Comparison of PsA and Fibromyalgia <i>A. Marchesoni, O. De Lucia, L. Rotunno, G. De Marco, M. Manara</i>	29
Mortality and Causes of Death in PsA <i>R. Arumugam, N.J. McHugh</i>	32
Osteoporosis and PsA <i>A. Del Puente, A. Esposito, A. Parisi, et al</i>	36
PsA: Need for Ultrasound in Everyday Clinical Practice <i>W. Grassi, M. Gutierrez</i>	39
Dynamic Contrast-enhanced MRI of Articular and Extraarticular Synovial Structures of the Hands in Patients with PsA <i>M.A. Cimmino, F. Barbieri, M. Boesen, et al</i>	44
New Developments in MRI of the Nail Unit <i>E. Soscia, C. Sirignano, O. Catalano, et al</i>	49
The Radiological Assessment of Axial Involvement in PsA <i>E. Lubrano, A. Marchesoni, I. Olivieri, et al</i>	54
Biomarker Development in PsA <i>C. Ritchlin</i>	57

Contents continued on back cover . . .

Synovial Biomarkers in PsA <i>U. Fiocco, F. Oliviero, P. Sfriso, et al</i>	61
Soluble Biomarkers May Differentiate Psoriasis from PsA <i>V. Chandran</i>	65
The Actual Role of Therapy with Traditional DMARD in PsA <i>E.R. Soriano</i>	67
Infliximab in PsA <i>F. Cantini, L. Niccoli, C. Nannini, O. Kaloudi, E. Cassara</i>	71
Etanercept in PsA <i>A. Spadaro, E. Lubrano, N. Ferrara, R. Scarpa</i>	74
Adalimumab in PsA <i>C. Salvarani, N. Pipitone, M. Catanoso, et al</i>	77
Screening and Monitoring of Latent Tubercular Infection in Patients Taking TNF-α Blockers for PsA <i>A. Sanduzzi, M. Bocchino, M. Atteno, et al</i>	82
Ustekinumab for Psoriasis and PsA <i>A.B. Gottlieb, A.M. Goldminz</i>	86
Treatment of PsA with TNF Inhibitors: Longer-term Outcomes Including Enthesitis and Dactylitis with Golimumab Treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL) <i>A. Kavanaugh, P. Mease</i>	90
Should We Consider TNF as the Only Target in Spondyloarthritis? <i>G. Ferraccioli, E. Gremese</i>	94
IL-6 Blockade: Tocilizumab in PsA <i>F. Atzeni, D. Ventura, A. Batticciotto, L. Boccassini, P. Sarzi-Puttini</i>	97
The Inhibitor of Costimulation of T Cells: Abatacept <i>F. Iannone, G. Lapadula</i>	100
Pharmacoeconomic Issues in PsA <i>I. Olivieri, S. D'Angelo, C. Palazzi, A. Padula, E. Lubrano, L.G. Mantovani</i>	103
Future Trends in Research in PsA <i>D.D. Gladman</i>	106